IN2014DN08830A - - Google Patents

Download PDF

Info

Publication number
IN2014DN08830A
IN2014DN08830A IN8830DEN2014A IN2014DN08830A IN 2014DN08830 A IN2014DN08830 A IN 2014DN08830A IN 8830DEN2014 A IN8830DEN2014 A IN 8830DEN2014A IN 2014DN08830 A IN2014DN08830 A IN 2014DN08830A
Authority
IN
India
Prior art keywords
eliciting
immune response
compositions
useful
individual
Prior art date
Application number
Other languages
English (en)
Inventor
Richard C Duke
Alex Franzusoff
Aurelia Haller
Thomas H King
Yingnian Lu
Victoria Kelley Hodson
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of IN2014DN08830A publication Critical patent/IN2014DN08830A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN8830DEN2014 2006-02-02 2007-02-02 IN2014DN08830A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
PCT/US2007/061572 WO2007092792A2 (fr) 2006-02-02 2007-02-02 Vaccin à base de levure destiné à induire une réponse immunitaire

Publications (1)

Publication Number Publication Date
IN2014DN08830A true IN2014DN08830A (fr) 2015-07-10

Family

ID=38345897

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8830DEN2014 IN2014DN08830A (fr) 2006-02-02 2007-02-02

Country Status (14)

Country Link
US (2) US7736642B2 (fr)
EP (2) EP1988919A4 (fr)
JP (3) JP5198290B2 (fr)
KR (2) KR101492524B1 (fr)
CN (2) CN104826102A (fr)
AU (1) AU2007212076B2 (fr)
BR (1) BRPI0706913A2 (fr)
CA (1) CA2638815A1 (fr)
IL (2) IL193196A (fr)
IN (1) IN2014DN08830A (fr)
MX (1) MX2008009929A (fr)
SG (2) SG169375A1 (fr)
TW (2) TW200806316A (fr)
WO (1) WO2007092792A2 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002039951A2 (fr) * 2000-11-15 2002-05-23 Globe Immune, Inc. Vaccins a base de cellules dendritiques et de levure, et leurs utilisations
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
WO2007092792A2 (fr) * 2006-02-02 2007-08-16 Globeimmune, Inc. Vaccin à base de levure destiné à induire une réponse immunitaire
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US9101578B2 (en) * 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
EP1998814A4 (fr) * 2006-05-11 2010-06-16 Novavax Inc Nouveaux vaccins contre l'influenza m2
US9511134B2 (en) * 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
AU2008214029B2 (en) 2007-02-02 2014-01-30 Globelmmune, Inc. Methods for producing yeast-based vaccines
EP2134358A1 (fr) * 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions et procédés pour l'ablation ciblée de la métasynthèse de thérapies ciblées pour le cancer
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
KR101781966B1 (ko) 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
EA201171436A1 (ru) * 2009-05-18 2012-04-30 Панацеа Биотек Лтд. Универсальная противогриппозная вакцина на основе рекомбинантного модифицированного вируса коровьей оспы анкара (mva)
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US20120015346A1 (en) * 2010-07-08 2012-01-19 New York Medical College Influenza virus detection and diagnosis
BR112013007946B1 (pt) * 2010-10-04 2022-07-12 Massachusetts Institute Of Technology Composições farmacêuticas e imunogênicas compreendendo polipeptídeos de hemaglutinina
WO2012048817A2 (fr) * 2010-10-15 2012-04-19 Bavarian Nordic A/S Vaccin contre la grippe à base d'un virus de la vaccine ankara recombinant, modifié
US9254320B2 (en) * 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2012106231A2 (fr) * 2011-01-31 2012-08-09 Baxter International Inc. Vecteurs viraux recombinants et procédés d'induction d'une réponse immunitaire hétéro sous-typique aux virus de la grippe a
EA028659B1 (ru) 2011-02-12 2017-12-29 Глоубиммьюн, Инк. Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
RU2690180C2 (ru) * 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
US20140377295A1 (en) * 2011-05-23 2014-12-25 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
BR112013032381B1 (pt) * 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
US9580475B2 (en) * 2011-06-20 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
KR102049928B1 (ko) 2011-08-17 2019-11-28 글로브이뮨 효모-muc1 면역요법 조성물 및 그 용도
EP2591798B1 (fr) * 2011-11-09 2014-11-19 Werner Lubitz Vaccin pour utilisation dans immunothérapie antitumorale
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
SG11201408652SA (en) 2012-06-26 2015-01-29 Biodesix Inc Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
EP2929351B1 (fr) * 2012-12-10 2019-10-09 The University of Queensland Compositions de biofragments sans cellules, et systèmes, dispositifs et procédés correspondants
WO2014151279A1 (fr) * 2013-03-15 2014-09-25 The Trustees Of The University Of Pennsylvania Vaccins possédant un antigène et une interleukine-23 formant adjuvant
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
US10226522B2 (en) * 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
KR20220062143A (ko) * 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
WO2015134606A1 (fr) 2014-03-05 2015-09-11 Orbis Health Solutions Llc Systèmes d'administration de vaccin à l'aide de particules de paroi cellulaire de levure
US10799567B2 (en) * 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
CA2973109A1 (fr) 2015-01-09 2016-07-14 Etubics Corporation Methodes et compositions pour la vaccination contre le virus ebola
WO2016168187A1 (fr) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Particules de type virus
WO2017023840A1 (fr) 2015-08-03 2017-02-09 Globeimmune, Inc. Compositions immunothérapeutiques de levure brachyury modifiée
JP6956067B2 (ja) * 2015-08-11 2021-10-27 オービス ヘルス ソリューションズ エルエルシー 細菌およびウイルスのワクチン戦略
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (fr) 2016-01-22 2017-07-26 Werner Lubitz Hôtes bactériens pour le traitement du cancer
JP2019513021A (ja) 2016-03-24 2019-05-23 ナントセル，インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
IL314202B1 (en) 2017-04-24 2026-04-01 Nantcell Inc Neoepitope vectors and methods for them
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
DE102017012109A1 (de) 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
WO2019222073A1 (fr) 2018-05-15 2019-11-21 Globeimmune, Inc. Lysats de levure recombinante pour induire des réponses immunitaires cellulaires
CN111315407B (zh) * 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
CA3138174A1 (fr) * 2019-05-21 2020-11-26 David James O'hagan Vaccination par voie orale a base de levures
CN116113424A (zh) * 2020-02-11 2023-05-12 赛托纳斯治疗公司 快速疫苗平台
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
AU2021254753A1 (en) 2020-04-14 2022-08-25 Nantcell, Inc. Yeast lysate COVID-19 vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
PT733113E (pt) * 1994-01-11 2007-08-10 Vlaams Interuniv Inst Biotech Vacina contra a gripe
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
JP5008244B2 (ja) * 2000-06-23 2012-08-22 ワイス・ホールディングズ・コーポレイション 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー
WO2002039951A2 (fr) 2000-11-15 2002-05-23 Globe Immune, Inc. Vaccins a base de cellules dendritiques et de levure, et leurs utilisations
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US20060024670A1 (en) * 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
US8007814B2 (en) 2004-06-16 2011-08-30 University Of Massachusetts Therapy for lysosomal enzyme deficiencies
WO2007092792A2 (fr) * 2006-02-02 2007-08-16 Globeimmune, Inc. Vaccin à base de levure destiné à induire une réponse immunitaire

Also Published As

Publication number Publication date
MX2008009929A (es) 2008-10-01
IL232518A0 (en) 2014-06-30
IL193196A (en) 2015-01-29
JP2013075899A (ja) 2013-04-25
KR20140029551A (ko) 2014-03-10
US20080003239A1 (en) 2008-01-03
AU2007212076B2 (en) 2012-10-18
US20100196411A1 (en) 2010-08-05
CN104826102A (zh) 2015-08-12
SG169375A1 (en) 2011-03-30
EP2468296A3 (fr) 2013-12-04
CN101405026A (zh) 2009-04-08
JP2009528987A (ja) 2009-08-13
CN101405026B (zh) 2015-04-22
TW200806316A (en) 2008-02-01
EP2468296A2 (fr) 2012-06-27
EP1988919A4 (fr) 2009-06-10
EP1988919A2 (fr) 2008-11-12
KR101492524B1 (ko) 2015-02-12
AU2007212076A1 (en) 2007-08-16
SG10201402236VA (en) 2014-08-28
WO2007092792A2 (fr) 2007-08-16
TW201412329A (zh) 2014-04-01
US7736642B2 (en) 2010-06-15
JP5198290B2 (ja) 2013-05-15
WO2007092792A3 (fr) 2008-02-28
IL193196A0 (en) 2011-08-01
KR20080089671A (ko) 2008-10-07
CA2638815A1 (fr) 2007-08-16
BRPI0706913A2 (pt) 2011-04-12
JP2015038147A (ja) 2015-02-26

Similar Documents

Publication Publication Date Title
IN2014DN08830A (fr)
WO2010019262A3 (fr) Vaccin polyvalent
WO2007024941A3 (fr) Vaccin polyvalent
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
WO2007120673A3 (fr) Peptides wt1 immunogènes et leurs méthodes d'utilisation
EP3725328A3 (fr) Nouvelles compositions d'adjuvants
TNSN07387A1 (en) C.perfringens alpha toxoid vaccine
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
WO2008148057A3 (fr) Compositions et procédés pour améliorer la réponse immunitaire à des vaccins
WO2006068663A3 (fr) Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
WO2006113214A3 (fr) Vaccin contre des souches pandemiques des virus de la grippe
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
EP2432504A4 (fr) Vaccins contre le virus de l'herpès simplex 2 : compositions et procédés pour déclencher une réponse immunitaire
CA2763359C (fr) Nouvelles souches de rotavirus humain et nouveaux vaccins
WO2009135199A3 (fr) Compositions vaccinales et procédés
HK1211980A1 (en) Multifunctional oral vaccine based on chromosome recombineering
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
WO2011100508A3 (fr) Procédés et compositions liés à des fusions glycoprotéine-immunoglobuline
WO2011074006A3 (fr) Composition de vaccin
WO2007120603A3 (fr) Peptides bcr-abl immunogènes et leurs méthodes d'utilisation
WO2007120860A3 (fr) Vaccins à base d'une nanoémulsion
WO2012103444A3 (fr) Compositions et réactifs immunogènes pour une préparation
WO2010080188A3 (fr) Vaccin ciblé par épitope contre le charbon